clinical trial · NCT04049760
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
Fabry Diseasemigalastat HCl 150 mg
brief summary
This is a long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects \> 12 Years of Age With Fabry Disease and Amenable GLA Variants
started
Oct 11, 2019
primary completion
Nov 29, 2024
completion
Nov 29, 2024
last updated
Feb 5, 2026
official title
A Long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects > 12 Years of Age With Fabry Disease and Amenable GLA Variants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol